Synonym
3-hydroxyquinidine; (3S)-3-Hydroxy Quinidine; 53467-23-5 3;-Hydroxy quinidine; (3S)-Hydroxyquinidine
IUPAC/Chemical Name
(1S,3S,4S,6R)-6-((S)-hydroxy(6-methoxyquinolin-4-yl)methyl)-3-vinylquinuclidin-3-ol
InChi Key
BSRUJCFCZKMFMB-LGWHJFRWSA-N
InChi Code
InChI=1S/C20H24N2O3/c1-3-20(24)12-22-9-7-13(20)10-18(22)19(23)15-6-8-21-17-5-4-14(25-2)11-16(15)17/h3-6,8,11,13,18-19,23-24H,1,7,9-10,12H2,2H3/t13-,18+,19-,20+/m0/s1
SMILES Code
[H][C@@]1(C[C@@H]2CC[N@]1C[C@]2(O)C=C)[C@@H](O)C3=C4C=C(OC)C=CC4=NC=C3
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
340.42
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Vozeh S, Bindschedler M, Ha HR, Kaufmann G, Guentert TW, Follath F.
Pharmacodynamics of 3-hydroxyquinidine alone and in combination with quinidine
in healthy persons. Am J Cardiol. 1987 Mar 1;59(6):681-4. doi:
10.1016/0002-9149(87)91192-1. PMID: 3825912.
2: Wooding-Scott RA, Smalley J, Visco J, Slaughter RL. The pharmacokinetics and
pharmacodynamics of quinidine and 3-hydroxyquinidine. Br J Clin Pharmacol. 1988
Oct;26(4):415-21. doi: 10.1111/j.1365-2125.1988.tb03400.x. PMID: 3190991; PMCID:
PMC1386563.
3: Bowers LD, Nelson KM, Connor R, Lais CJ, Krauss E. Evidence supporting
3(S)-3-hydroxyquinidine-associated cardiotoxicity. Ther Drug Monit.
1985;7(3):308-12. doi: 10.1097/00007691-198507030-00013. PMID: 4049469.
4: Wooding-Scott RA, Visco J, Slaughter RL. Total and unbound concentrations of
quinidine and 3-hydroxyquinidine at steady state. Am Heart J. 1987 Feb;113(2 Pt
1):302-6. doi: 10.1016/0002-8703(87)90269-9. PMID: 3812182.
5: Ackerman BH, Olsen KM, Kennedy EE, Taylor EH, Chen BH, Jordan D, Ackerman DJ.
Disposition of 3-hydroxyquinidine in patients receiving initial intravenous
quinidine gluconate for electrophysiology testing of ventricular tachycardia.
DICP. 1989 May;23(5):375-8. doi: 10.1177/106002808902300504. PMID: 2728524.
6: Juliard JM, Heckle J, Jaillon P, Poirier JM, Aubry JP, Cheymol G, Jarreau FX.
Comparaison des effets électrophysiologiques cardiaques de la quinidine, de la
3-hydroxy-quinidine et de la 3-hydroxy-hydroquinidine chez le chien anesthésié.
Etude des relations effets--concentrations plasmatiques [Comparison of the
cardiac electrophysiologic effects of quinidine, 3-hydroxyquinidine and
3-hydroxyhydroquinidine in the anesthesized dog. Study of plasma dose response
relations]. Arch Mal Coeur Vaiss. 1983 Jun;76(6):670-8. French. PMID: 6414408.
